Journal of Antivirals & Antiretrovirals
Open Access

Antiviral Resistance in Influenza Viruses: Mechanisms and Management Strategies

Ethan Williams^{* *}Correspondence: Ethan Williams, Department of Virology, University of California, San Francisco, USA, Email:

Author info »

Description

Influenza viruses are among the most common pathogens responsible for seasonal outbreaks and occasional pandemics, posing significant public health challenges worldwide. The rapid evolution of influenza viruses through genetic mutations and reassortment events contributes to their ability to evade host immunity and antiviral interventions. One of the key issues complicating influenza management is the emergence and spread of antiviral resistance, which diminishes the effectiveness of available treatments. This perspective describes the mechanisms underlying antiviral resistance in influenza viruses, discusses current management strategies, and outlines future directions for combating this ongoing threat. Influenza viruses belong to the family Orthomyxoviridae and are classified into types A, B, C, and D based on their genetic and antigenic characteristics. Among these, influenza A and B viruses are responsible for seasonal epidemics in humans, while influenza A viruses, in particular, have the potential to cause pandemics due to their ability to undergo frequent genetic changes. The primary targets of antiviral drugs against influenza are the viral Neuraminidase (NA) enzyme and the viral matrix 2 (M2) ion channel protein. Neuraminidase Inhibitors (NAIs), such as oseltamivir, zanamivir, and peramivir, and adamantanes, including amantadine and rimantadine, targeting the M2 ion channel, have been used extensively for the treatment and prophylaxis of influenza infections. However, the emergence of resistance to these antivirals presents a significant challenge to their clinical efficacy. Resistance to adamantanes arises primarily due to mutations in the M2 protein, particularly at positions 26, 27, 30, 31, and 34, which interfere with drug binding and ion channel function. In contrast, resistance to NAIs is mainly mediated by mutations in the neuraminidase gene, particularly at residues 119, 274, 292, and 294, affecting the enzymatic activity and drug binding affinity.

The mechanisms of antiviral resistance in influenza viruses are complex and multifactorial. Genetic mutations that confer resistance can arise spontaneously during viral replication or can be transmitted between viruses through reassortment events.

The high mutation rate of influenza viruses, facilitated by the error-prone RNA-dependent RNA polymerase and the segmented nature of its genome, contributes to the rapid emergence and dissemination of resistant strains. Importantly, influenza viruses can develop resistance to multiple antiviral drugs simultaneously, further limiting treatment options. Managing antiviral resistance in influenza requires a multifaceted approach that includes surveillance, prevention strategies, and the development of alternative treatment options. Surveillance programs monitor circulating influenza strains for the presence of antiviral resistance mutations, providing important data to guide treatment recommendations. Real-time monitoring and reporting of resistance patterns enable public health authorities to make informed decisions regarding antiviral use and pandemic preparedness. Prevention strategies focus on reducing the spread of resistant influenza strains through vaccination campaigns and infection control measures. Annual influenza vaccination remains the cornerstone of influenza prevention, reducing the overall burden of disease and the likelihood of antiviral use. Vaccination not only lowers the risk of influenza infection but also reduces the need for antiviral treatment, thereby potentially limiting the emergence of resistance.

Development of alternative antiviral therapies is essential to address the challenge of resistance. Research efforts are underway to identify novel drug targets and develop new classes of antiviral agents with distinct mechanisms of action. Novel NAIs, such as laninamivir and peramivir, have been developed to overcome resistance to older NAIs like oseltamivir. Similarly, investigational drugs targeting viral polymerase or host cell factors essential for viral replication are being explored as potential alternatives to existing therapies. Combination antiviral therapy represents another strategy to combat resistance by targeting multiple viral proteins simultaneously. The rationale behind combination therapy is to reduce the likelihood of resistance emergence and improve treatment outcomes. For instance, combining NAIs with inhibitors of viral polymerase or host cell proteases has shown promise in preclinical and clinical studies, demonstrating enhanced antiviral activity and delayed resistance development.

Antiviral stewardship programs play a critical role in optimizing the use of antiviral drugs and minimizing the selective pressure for resistance. These programs promote judicious prescribing practices, encourage adherence to treatment guidelines, and educate healthcare providers and patients about the importance of antiviral resistance prevention. By ensuring appropriate use of antiviral drugs, stewardship programs aim to preserve treatment efficacy and prolong the lifespan of available therapies.

Advancements in diagnostic technologies, such as rapid molecular assays and next-generation sequencing, have revolutionized the detection and characterization of antiviral resistance in influenza viruses. These tools enable rapid identification of resistance mutations directly from clinical specimens, facilitating timely clinical decision-making and epidemiological surveillance. Integration of molecular diagnostics into routine influenza testing protocols enhances the capacity to monitor resistance patterns and inform public health interventions. Global collaboration and data sharing are essential for addressing the threat of antiviral resistance in influenza viruses on a global scale. International networks, such as the World Health Organization (WHO) Global Influenza Surveillance and Response System (GISRS), facilitate the exchange of influenza virus isolates and resistance data among laboratories worldwide. These collaborations enable coordinated efforts to monitor influenza activity, track resistance trends, and develop evidence-based recommendations for antiviral use. Future research directions in antiviral resistance include elucidating the genetic determinants of resistance, understanding the fitness costs associated with resistance mutations, and exploring novel therapeutic targets. Advances in structural biology and computational modeling offer opportunities to design drugs that are less prone to resistance and more effective against diverse influenza strains. Additionally, integrating genomic surveillance with clinical and epidemiological data will provide insights into the dynamics of resistance emergence and transmission.

Conclusion

In conclusion, antiviral resistance remains a significant challenge in the management of influenza viruses, threatening the effectiveness of available treatments and pandemic preparedness efforts. The complex interplay of viral evolution, genetic diversity, and selective pressure necessitates ongoing vigilance and innovation in antiviral drug development and public health strategies. By employing a comprehensive approach that combines surveillance, prevention, stewardship, and research, we can mitigate the impact of antiviral resistance and safeguard global health against influenza threats now and in the future.